Top NPS Pharmaceuticals, Inc. Exec's View On The Megadeal Fallout For Biotechs

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Sometime soon, it’s entirely possible that Pfizer will buy AstraZeneca for a price that would exceed the gross national product of all but about 50 countries worldwide. Should that happen, a long, complicated process will unfold. Pfizer (NYSE: PFE) will talk about bringing together two titans with franchises in big fields like oncology, inflammation, and cardiovascular disease, while its financial people tout massive tax savings. Shareholders of AstraZeneca (NYSE: AZN) will walk away with a lot of extra cash and perhaps stock.

Help employers find you! Check out all the jobs and post your resume.

Back to news